CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY

(19)

(11)

EP 2 841 068 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	06.03.2019 Bulletin 2019/10

(45)	Mention of the grant of the patent:
	28.11.2018 Bulletin 2018/48

(21)	Application number: 13722318.6

(22)	Date of filing: 23.04.2013

(51)

International Patent Classification (IPC):

A61K 31/4412^(2006.01)

A61K 31/53^(2006.01)

(86)	International application number:
	PCT/EP2013/058413

(87)	International publication number:
	WO 2013/160317 (31.10.2013 Gazette 2013/44)

(54)	CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY CRHR1-ANTAGONISTEN ZUR VERWENDUNG BEI DER BEHANDLUNG VON PATIENTEN MIT CRH-ÜBERAKTIVITÄT ANTAGONISTES DE CRHR1 POUR UNE UTILISATION DANS LE TRAITEMENT DE PATIENTS PRÉSENTANT UNE HYPERACTIVITÉ DE LA CRH

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME

(30)

Priority:

23.04.2012 GB 201207102
23.04.2012 EP 12165231

(43)	Date of publication of application:
	04.03.2015 Bulletin 2015/10

(73)	Proprietor: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
	80539 München (DE)

(72)	Inventor:
	HOLSBOER, Florian 80805 Munich (DE)

(74)	Representative: Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
	Elisenhof Elisenstraße 3 80335 München 80335 München (DE)

(56)

References cited: :

WO-A1-95/33750
WO-A1-2004/094420
US-A- 6 060 478
US-A1- 2007 281 919
US-B1- 7 067 664

WO-A1-02/072202
WO-A1-2007/137227
US-A- 6 107 301
US-A1- 2008 194 589

LIU Z ET AL: "Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 404, no. 3, 1 September 2006 (2006-09-01), pages 358-362, XP027885387, ISSN: 0304-3940 [retrieved on 2006-09-01]
BOGUSLAWA BUDZISZEWSKA ET AL: "Regulation of the Human Corticotropin-Releasing-Hormone Gene Promoter Activity by Antidepressant Drugs in Neuro-2A and AtT-20 Cells", NEUROPSYCHOPHARMACOLOGY, vol. 29, no. 4, 1 April 2004 (2004-04-01), pages 785-794, XP055077200, ISSN: 0893-133X, DOI: 10.1038/sj.npp.1300379
YUHPYNG L. CHEN ET AL: "Synthesis and SAR of 2-Aryloxy-4-alkoxy-pyridines as Potent Orally Active Corticotropin-Releasing Factor 1 Receptor Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 5, 1 March 2008 (2008-03-01), pages 1377-1384, XP055077125, ISSN: 0022-2623, DOI: 10.1021/jm070578k
Brendon Binneman ET AL: "A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression", The American journal of psychiatry, 1 May 2008 (2008-05-01), pages 617-620, XP055143057, United States DOI: 10.1176/appi.ajp.2008.07071199 Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pubmed/184 13705

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).